MAPT and Alzheimer disease: Finally, in the subset with repeated tau biomarker assessments, an interaction effect of diagnosis × time was observed for plasma pTau181 (β = 0.35, P < 0.001), meaning plasma pTau181 levels increased more steeply in MCI/AD than in SCD (Fig. 4).